TY - JOUR
T1 - Diagnostic microbiologic methods in the GEMS-1 case/control study
AU - Panchalingam, Sandra
AU - Antonio, Martin
AU - Hossain, Anowar
AU - Mandomando, Inacio
AU - Ochieng, Ben
AU - Oundo, Joseph
AU - Ramamurthy, T.
AU - Tamboura, Boubou
AU - Zaidi, Anita K.M.
AU - Petri, William
AU - Houpt, Eric
AU - Murray, Patrick
AU - Prado, Valeria
AU - Vidal, Roberto
AU - Steele, Duncan
AU - Strockbine, Nancy
AU - Sansonetti, Philippe
AU - Glass, Roger I.
AU - Robins-Browne, Roy M.
AU - Tauschek, Marija
AU - Svennerholm, Ann Marie
AU - Kotloff, Karen
AU - Levine, Myron M.
AU - Nataro, James P.
N1 - Funding Information:
Financial support. This work was supported by the Bill & Melinda Gates Foundation (grant number 38874). Supplement sponsorship. This article was published as part of the supplement entitled “The Global Enteric Multicenter Study (GEMS),” sponsored by the Bill & Melinda Gates Foundation. Potential conflicts of interest. All authors: No reported conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
PY - 2012/12/15
Y1 - 2012/12/15
N2 - To understand the etiology of moderate-to-severe diarrhea among children in high mortality areas of sub-Saharan Africa and South Asia, we performed a comprehensive case/control study of children aged <5 years at 7 sites. Each site employed an identical case/control study design and each utilized a uniform comprehensive set of microbiological assays to identify the likely bacterial, viral and protozoal etiologies. The selected assays effected a balanced consideration of cost, robustness and performance, and all assays were performed at the study sites. Identification of bacterial pathogens employed streamlined conventional bacteriologic biochemical and serological algorithms. Diarrheagenic Escherichia coli were identified by application of a multiplex polymerase chain reaction assay for enterotoxigenic, enteroaggregative, and enteropathogenic E. coli. Rotavirus, adenovirus, Entamoeba histolytica, Giardia enterica, and Cryptosporidium species were detected by commercially available enzyme immunoassays on stool samples. Samples positive for adenovirus were further evaluated for adenovirus serotypes 40 and 41. We developed a novel multiplex assay to detect norovirus (types 1 and 2), astrovirus, and sapovirus. The portfolio of diagnostic assays used in the GEMS study can be broadly applied in developing countries seeking robust cost-effective methods for enteric pathogen detection.
AB - To understand the etiology of moderate-to-severe diarrhea among children in high mortality areas of sub-Saharan Africa and South Asia, we performed a comprehensive case/control study of children aged <5 years at 7 sites. Each site employed an identical case/control study design and each utilized a uniform comprehensive set of microbiological assays to identify the likely bacterial, viral and protozoal etiologies. The selected assays effected a balanced consideration of cost, robustness and performance, and all assays were performed at the study sites. Identification of bacterial pathogens employed streamlined conventional bacteriologic biochemical and serological algorithms. Diarrheagenic Escherichia coli were identified by application of a multiplex polymerase chain reaction assay for enterotoxigenic, enteroaggregative, and enteropathogenic E. coli. Rotavirus, adenovirus, Entamoeba histolytica, Giardia enterica, and Cryptosporidium species were detected by commercially available enzyme immunoassays on stool samples. Samples positive for adenovirus were further evaluated for adenovirus serotypes 40 and 41. We developed a novel multiplex assay to detect norovirus (types 1 and 2), astrovirus, and sapovirus. The portfolio of diagnostic assays used in the GEMS study can be broadly applied in developing countries seeking robust cost-effective methods for enteric pathogen detection.
UR - http://www.scopus.com/inward/record.url?scp=84870036414&partnerID=8YFLogxK
U2 - 10.1093/cid/cis754
DO - 10.1093/cid/cis754
M3 - Article
C2 - 23169941
AN - SCOPUS:84870036414
SN - 1058-4838
VL - 55
SP - S294-S302
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - SUPPL. 4
ER -